Adaptación y evaluación de las propiedades de medición de la versión brasileña de la Self-efficacy for Appropriate Medication Adherence Scale by Pedrosa, Rafaela Batista dos Santos & Rodrigues, Roberta Cunha Matheus
Rev. Latino-Am. Enfermagem
2016;24:e2692
DOI: 10.1590/1518-8345.0167.2692
www.eerp.usp.br/rlae
Original Article
How to cite this article
Pedrosa RBS, Rodrigues RCM. Adaptation and evaluation of the measurement properties of the Brazilian version 
of the Self-efficacy for Appropriate Medication Adherence Scale. Rev. Latino-Am. Enfermagem. 2016;24:e2692. 
[Access ___ __ ____]; Available in: ____________________. DOI: http://dx.doi.org/110.1590/1518-
8345.0167.2692.
daymonth year
URL
Adaptation and evaluation of the measurement properties of the 
Brazilian version of the Self-efficacy for Appropriate Medication 
Adherence Scale1
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Objectives: to undertake the cultural adaptation of, and to evaluate the measurement properties 
of, the Brazilian version of the Self-efficacy for Appropriate Medication Adherence Scale in coronary 
heart disease (CHD) patients, with outpatient monitoring at a teaching hospital. Method: the 
process of cultural adaptation was undertaken in accordance with the international literature. The 
data were obtained from 147 CHD patients, through the application of the sociodemographic/
clinical characterization instrument, and of the Brazilian versions of the Morisky Self-Reported 
Measure of Medication Adherence Scale, the General Perceived Self-Efficacy Scale, and the Self-
efficacy for Appropriate Medication Adherence Scale. Results: the Brazilian version of the Self-
efficacy for Appropriate Medication Adherence Scale presented evidence of semantic-idiomatic, 
conceptual and cultural equivalencies, with high acceptability and practicality. The floor effect was 
evidenced for the total score and for the domains of the scale studied. The findings evidenced 
the measure’s reliability. The domains of the Brazilian version of the Self-efficacy for Appropriate 
Medication Adherence Scale presented significant inverse correlations of moderate to strong 
magnitude between the scores of the Morisky scale, indicating convergent validity, although 
correlations with the measure of general self-efficacy were not evidenced. The validity of known 
groups was supported, as the scale discriminated between “adherents” and “non-adherents” to 
the medications, as well as to “sufficient dose” and “insufficient dose”. Conclusion: the Brazilian 
version of the Self-efficacy for Appropriate Medication Adherence Scale presented evidence of 
reliability and validity in coronary heart disease outpatients.
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Introduction
Although it is highly prevalent worldwide(1), recent 
studies indicate that the advances in the treatment 
of Coronary Heart Disease (CHD) have contributed 
to a decline observed in the rates of hospitalization 
and in mortality through Acute Myocardial Infarction 
(AMI)(1-2). Evidence demonstrates the efficacy of 
the use of cardioprotective therapy (Beta blockers, 
Angiotensin-Converting Enzyme Inhibitors (ACE-
inhibitors) or Angiotensin-Receptor Blockers (ARBs), 
statins and antiplatelets) in the secondary prevention 
of CHD, the combined use of this therapy being widely 
recommended(3). In addition to this, the use of these 
medications was associated with the reduction in the 
relative risk of death through CHD (2-3). In conjunction 
with the cardioprotective drugs, the use of medications 
for relieving symptoms is also related to the patients’ 
greater tolerance to the symptoms of CHD(1,3). As 
a result, the prognosis of CHD is closely related to 
adherence to the cardioprotective medications and to 
medications which relieve the symptoms. 
Adherence, is defined as the extent to which the 
patients follow the guidance for the treatment which 
they are provided with by the doctor and/or other health 
professionals(4). Therefore, nonadherence occurs when 
the patient’s behavior does not coincide with these 
recommendations(5).
For better comprehension of the construct of 
medication adherence, some theories have been 
utilized(6), among them Bandura’s Social-Cognitive 
Theory; self-efficacy is this theory’s central concept. 
Self-efficacy may be defined as a belief or trust that one 
can successfully undertake a specific action, in order to 
achieve the desired result(7).
The complexity of medication adherence goes 
beyond understanding the construct itself, and 
encompasses the extreme difficulty involved in its 
accurate measurement. Various methods are available 
in the literature(8), including the self-reported scales. 
Among the reliable and valid tools for evaluation of self-
efficacy, for the behavior of adherence, the Self-efficacy 
for Appropriate Medication Adherence Scale (SEAMS)(9), 
an American scale, stands out. This was constructed in 
order to assess self-efficacy for medication adherence 
among individuals with low educational levels. This 
scale presented adequate measurement properties, 
when applied in 436 patients with CHD and other 
comorbidities. The authors do not know of any self-
reported instruments for the measurement of self-
efficacy, for the behavior of medication adherence, in 
the Brazilian context. 
As a result, this study’s objectives were to 
undertake the cultural adaptation of the SEAMS to 
Brazilian Portuguese and assess its measurement 
properties among patients with CHD being treated on 
an outpatient basis. The specific objectives were to 
ascertain practicality, acceptability, ceiling and floor 
effect, reliability and convergent validity, and known 
groups validity. This research’s findings may guide more 
efficacious conducts in regard to strengthening the self-
efficacy for adherence to drug therapy among coronary 
heart disease (CHD) patients.
Methods
The methodological procedure of cultural adaptation 
The following stages were used for the process 
of translation and adaptation: translation – following 
the obtaining of consent from the author, the SEAMS 
was translated to Portuguese by two independent 
bilingual translators whose mother tongue is Brazilian 
Portuguese, only one of these being informed about 
the scale’s concepts and objectives(10); synthesis of the 
translations – the translated versions (T1 and T2) were 
analyzed and compared by the researchers and by a 
professional mediator-translator(10). The discrepancies 
were analyzed until consensus was obtained – the 
translated version of the SEAMS (T1-2); back translation 
– the translated version of the SEAMS was translated 
back into English by two other independent bilingual 
translators, who had not participated in the first stage, 
whose mother language was English and who were not 
aware of the instrument’s concepts/purposes. At the 
end of this stage, the following versions were obtained 
– back-translation 1 (BT1) and back-translation 2 (BT2); 
evaluation by a Committee of Judges: made up of five 
bilingual experts who evaluated the translated version 
in relation to the semantic and idiomatic, cultural and 
conceptual equivalencies(10) and pre-test – the adapted 
version was applied in 10 patients with CHD being 
treated on an outpatient basis. After responding to each 
item of the scale, the participants were interviewed in 
order to investigate the difficulties perceived in relation 
to the understanding of the statements and the response 
scale, as well as to detect terms which were difficult to 
understand. 
Methodological procedures for evaluation of the 
measurement properties 
The research locale
The study was undertaken in the cardiology 
outpatient center – Ischemic Heart Disease subspeciality 
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– of a teaching hospital in the nonmetropolitan region of 
the State of São Paulo.
Subjects
A total of 147 patients took part in this study, with 
previous clinical manifestation of unstable angina and/or 
acute myocardial infarction, receiving treatment on an 
outpatient basis, with a period of over six months since 
the last event, with a view to excluding those patients 
known to be clinically unstable, whose drug therapy is 
frequently modified, which could influence their behavior 
of adherence to the drug treatment(2-3). Patients in 
continuous use of cardioprotective drugs and/or drugs 
for relieving the symptoms for at least two months 
were included, as this is a period in which the patient is 
familiarized with the drug treatment prescribed. Those 
patients who presented inability for effective verbal 
communication were excluded. 
Sampling procedure and sample size 
The sample was made up of patients attended in 
the above-mentioned service, enrolled non-randomly, 
in October 2013 – January 2014. The sample size was 
calculated using the Spearman correlation coefficients, 
between the SEAMS scores and the measures of 
medication adherence, obtained in a pilot-study (n=15). 
Considering correlation coefficients between 0.30 and 
0.40, and values of α=0.05 and beta=0.9, the minimum 
number of 105 subjects was calculated. Losses being 
foreseen, the sample size was extended to 147 subjects. 
Data collection procedure 
The data were obtained by the researcher, 
individually, in a private environment, in accordance 
with the stages shown below. 
- First stage: consent to participate in the study was 
obtained through the signing of the Terms of Free 
and Informed Consent (TFIC), and information was 
collected regarding sociodemographic and clinical 
characterization, through interview and consulting 
medical records. The following were applied: the adapted 
version of SEAMS, the Brazilian versions of the Morisky 
Self-Reported Measure of Medication Adherence Scale 
(MMAS-4) and of the General Perceived Self-efficacy 
Scale (GSE), as well as measurements of adherence 
– proportion of adherence and global evaluation of 
medication adherence.
- Second stage: the Brazilian version of the SEAMS 
was reapplied (retest) in a proportion of the subjects 
who participated in the application (test), in similar 
conditions, with an interval of fifteen days between the 
first and second application. In this stage, only those 
participants whose return was arranged in the above-
mentioned service took part (n=34).
Data collection instruments 
Instrument for sociodemographic and clinical 
characterization: the instrument constructed and 
subjected to content validity in a previous study was 
used(11).
Definition of the drug therapy evaluated: the drug 
therapy evaluated was related to reduction in CHD’s 
morbidity and mortality – lifesaving therapy – (that is, 
ACE-inhibitors, ARBs, Beta blockers, antiplatelet drugs 
and statins) and two other drugs which improve the 
signs and symptoms associated with coronary heart 
disease (that is to say, digitalis, diuretics and nitrates).
Morisky Self-Reported Measure of Medication 
Adherence Scale (MMAS-4): an instrument constituted 
by four questions relating to adherence to the drug 
treatment, assessing forgetting, carelessness, 
interruption of the use of the drug as a result of 
perceiving improvement, and interruption of the therapy 
due to perceiving worsening in the clinical situation(12). 
The Brazilian version of the Morisky scale will be used(13). 
In the Brazilian version, a Likert-type response scale 
was used, of 4 to 5 points, varying from (1) Never to 
(5) Daily; (1) Never to (5) Always and (1) Never to (4) 
Always. The sum of the responses to the four items 
generates a score between 4 and 18; higher scores 
indicate low adherence; lower scores, high adherence. 
- Self-reported measure of adherence: according 
to proportion of medication adherence and global 
evaluation of medication adherence. 
Proportion of medication adherence: this instrument 
is made up of four fields covering: 1. Description of 
name, dose and how to take all the prescribed drugs; 
2. Description of the drugs used on the day before the 
interview, by dose and how they are to be taken; 3. 
Drugs used the previous week and 4. Drugs used in the 
month prior to the interview. Fields 2 and 3, referent 
to the previous day and week, respectively, aimed to 
obtain more accurate responses through minimization of 
the memory bias. Only data from field 4, referent to the 
use of medication in the previous month will be used for 
calculating the proportion of adherence. The adherence 
was calculated based on the doses omitted, according 
to the following calculation: [(doses prescribed – doses 
missed) x 100/doses prescribed](14). The variable of 
adherence was treated as continuous (percentage of the 
doses taken in the month immediately preceding the 
interview) and categorical: appropriate dose (dose used 
≥80% of the dosage prescribed) and insufficient dose 
(dose used <80% of the dosage prescribed). For the 
patients who made use of more than one medication, the 
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final proportion of adherence was calculated by the mean 
of the percentages of adherence to each medication. 
The participants who made use of a dose which was 
above that prescribed had their values converted to the 
corresponding rates below 100%; that is, the participant 
with 120% adherence, as she exceeded complete 
adherence by 20%, would correspond to a value of 80% 
of adherence. 
- Global evaluation of adherence: in this measurement, 
besides the proportion of taking of medications, the 
way in which these are taken, the frequency and the 
necessary care for administering the medications was 
evaluated, taking into account the association with 
time markers: fasting, breakfast, lunch, dinner, and 
at bedtime. Therefore, the adherence, according to 
the dosage of the medications and care taken, termed 
global evaluation of adherence, was evaluated based in 
the following classification: Group I - appropriate dose 
and care for the prescription; Group II – correct dose 
and inadequate care; Group III - incorrect dose and 
inadequate care, and Group IV – inadequate dose and 
inadequate care. “Inadequate care” is considered to be 
the use of one or more medications, in which how they 
should be taken (number and frequency of medications) 
and association with time markers (fasting, breakfast 
and lunch), are not in accordance with the medical 
prescription. The participants classified in Group I were 
considered “adherent” and those classified in the other 
groups, as “nonadherent”(15).
- General Perceived Self-efficacy Scale (GSE): an 
instrument created by Schwarzer and Jerusalem(16), 
which is unidimensional and made up of 10 items, which 
refer to how to deal with success in a specified situation. 
The participant responds to the instrument through a 
five point Likert response scale which varies from 1 
(totally disagree) to 5 (totally agree). The total score 
has a variation from 10 to 50. A high score signifies a 
high perception of self-efficacy. The version adapted to 
Brazilian Portuguese was used(17).
- Self-efficacy for Appropriate Medication Adherence 
Scale (SEAMS): this is made up of 13 items, divided in two 
domains: self-efficacy for taking medications in difficult 
circumstances (07 items) and self-efficacy to continue 
to take the medication, under uncertain circumstances 
(06 items). In order to answer the instrument, the 
participant must indicate his or her level of confidence 
in relation to the correct use of the medications; the 
response can vary from 1 to 3, with 1 (not confident), 2 
(little confident), and 3 (very confident). The total score, 
which consists of the sum of the responses, can vary 
between 13 and 39; the higher the score, the greater 
the self-efficacy for adherence to the drug treatment(9).
Analysis of the data 
- Analysis of the Content Validity: the Content Validity 
Index (CVI) was used for evaluation of the semantic-
idiomatic, conceptual and cultural equivalencies. 
This measures the proportion of judges who are in 
agreement regarding the items and general aspects 
evaluated(10).  The items’ relevance and representativity 
was evaluated, through a Likert-type scale with scores 
varying between 1 and 4 (1= not relevant or not 
representative, 2= requiring major revision in order to 
be representative, 3= requiring minor revision in order 
to be representative, 4= relevant or representative). 
The CVI was calculated through the sum of agreement 
of the items which received scores of “3” or “4”, divided 
by the total number of responses. The items with scores 
of “1” or “2” were revised. 
- Descriptive analysis, of the reliability and validity of the 
Brazilian version of the SEAMS: the collected data were 
inserted into an electronic spreadsheet in the Statistical 
Package for the Social Sciences (SPSS) program, version 
17.0, for Windows, for the statistical analyses. 
- Descriptive analysis: tables of frequency and 
measurements of position and dispersion for the clinical 
and sociodemographic characterization data and for 
the scores of the scales used were made. Practicality 
was evaluated through the mean time spent in the 
application and the acceptability by the percentage of 
participants who responded to all the items(18). The floor 
effect, which is equivalent to the 10% of the scale’s 
worst possible results, and the ceiling effect, which 
corresponds to the 10% of the scale’s best possible 
results, were evaluated(19).
- Evaluation of reliability: the Cronbach alpha coefficient 
was used to calculate the internal consistency, with a 
Cronbach alpha of >0.70 being established as evidence 
of satisfactory internal consistency(20). In order to 
evaluate the stability of the measure, the Intraclass 
Correlation Coefficient (ICC) was used, with ICC >0.7 
being considered satisfactory(21).
- Calculation of the construct validity: the convergent 
construct validity and the validity of known or contrasted 
groups were tested.  In order to estimate the convergent 
construct validity, Spearman’s correlation coefficient was 
used in order to test the correlation between the scores 
of the Brazilian versions of the SEAMS, the GSE and the 
MMAS-4, considering the coefficients of <0.30 to be of 
weak magnitude, those between 0.30 and 0.50 to be of 
moderate magnitude, and those >0.50 to be of strong 
magnitude(22). Negative correlations of strong magnitude 
were hypothesized between the domains of the Brazilian 
version of the SEAMS and the total score for the MMAS-4, 
and significant positive correlations of strong to moderate 
magnitude between the SEAMS and the GSE. 
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The construct validity of known or contrasted groups 
was tested through the use of the Mann-Whitney test, in 
order to ascertain the instrument’s capacity to distinguish 
between the participants classified as appropriate dose 
or insufficient dose, according to the self-reported 
measurement of proportion of adherence, as well as those 
considered to be adherent or nonadherent to the drug 
therapy, according to the global evaluation of adherence. 
It was hypothesized that the participants classified as 
“nonadherent” and “insufficient dose” would present the 
lower self-efficacy for medication adherence, according to 
the proportion of medication adherence. 
A level of significance of 5% was adopted. 
Ethical aspects 
The study was approved by the university’s 
Research Ethics Committee (Opinion  N. 254.844/2013) 
and all the patients enrolled signed the TFIC.
Results
Methodological procedure of cultural adaptation 
The results of the content validation (CVI) 
evidenced between 0.80 and 1.0 in 11 of the 13 
items evaluated. Only items 11 and 12 obtained 
CVI= 0.60, these being revised in order to obtain 
consensus between the judges. However, some of the 
experts made suggestions regarding the presentation 
of the instrument, which were taken into account. As 
a result, the design was altered and the numbering 
was removed from the response scale, this being 
considered not to be important for the respondents. 
The Brazilian version of the SEAMS was evaluated 
by the Committee of Judges a second time, and 
submitted to the pre-test stage. In this stage, the 
respondents reported understanding the items, and 
denied difficulties for interpreting the response scale. 
Descriptive evaluation and evaluation of reliability, 
and construct validity
Sociodemographic and clinical characterization 
A predominance of men was observed (68.0%), 
with a mean age of 59.9 (Standard-Deviation - sd = 
9.6) years old, economically inactive (72.8%), with a 
mean family income of 2.7 (sd=1.1) Minimum-Salaries 
(MS)/month (Table 1).
Variable % Mean (sd)* Median Variation
Sex
Male 68.0
Age 59.9 (9.6) 60.0 34-84
Education – in years  (n=152) 5.3 (3.4) 4.0 0-16
Marital situation 
Married/cohabiting 69.1
Single 12.2
Separated/divorced 10.9
Widowed 6.8
Employment status
Inactive 72.8
Active 23.1
Housewife/husband 4.0
Family income (in MS*) 2.7 (1.1) 3.0 0-5
Characterization of the coronary heart disease
Infarction of the myocardium  83.7
Unstable angina 13.6
Number of previous AMIs†  (n=147) 1.2 (0.8) 1.0 0-5.0
Number of associated symptoms 1.7 (1.5) 1.0 0-5.0
Signs and symptoms (in the last months)  
Precordialgia 38.8
Dyspnea 32.0
Arrhythmia  22.4
Syncope 0.7
Table 1 - Sociodemographic and clinical characteristics of the CHD patients (n=147). Campinas, SP, Brazil, 2014
(continue...)
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The majority of the patients (83.9%) had been 
diagnosed with Myocardial Infarction (MI) (in isolation 
or associated with post-MI angina) and 2.9 (SD=1.2), 
with associated clinical conditions and/or risk factors. All 
the patients reported symptoms in the month prior to 
the interview, with a mean of 1.7 (sd=1.5) associated 
symptoms. The mean use of 6.4 (sd=1.9) medications 
per day was observed. 
Practicality, acceptability and ceiling and floor effects
The results suggest that the Brazilian version of the 
SEAMS is an instrument which is easy to apply, with a 
mean application time of 3 minutes (sd=0.5). All the 
participants responded to all the items of the SEAMS, 
which shows the high acceptability of the scale. The 
analysis of the mean and median values of the total 
score of the Brazilian version of the SEAMS showed high 
self-efficacy for medication adherence. The evaluation 
of the ceiling and floor effects indicated a ceiling effect 
for the total score and for the domains of the SEAMS 
(Table 2). 
Table 1 - (continuation)
Variable % Mean (sd)* Median Variation
Number of associated clinical conditions and/or risk factors 2.9 (1.2) 3.0 0-6.0
Systemic Arterial Hypertension (SAH) 94.6
Dyslipidemia 65.3
Smoking tobacco 67.3
Diabetes mellitus (DM) 44.9
Obesity (BMI>30kg/m2) 10.2
Treatment  
Angioplasty and/or surgical revascularization 55.1
Clinical 44.9
Number of medications in use  6.4 (1.9) 6.0 2-12
*MS= Minimum-salary, of R$724,00, Brazil, 2014; †AMI – Acute Myocardial Infarction 
SEAMS* – Domains N. of items Mean (sd) Median
Variation 
observed % Floor % Ceiling
Self-efficacy for taking medications, under difficult 
circumstances 7 20.2 (1.9) 21.0 9-21 0.0 83.7
Self-efficacy for continuing to take medications 
when the circumstances which permeate this 
action are uncertain
6 17.2 (1.9) 18.0 7-18 0.0 83.0
Total score 13 37.3 (3.5) 39.0 17-39 0.0 79.6
Table 2 - Descriptive analysis of the domains and ceiling and floor effects of the Self-efficacy for Appropriate Medication 
Adherence Scale (n=147). Campinas, SP, Brazil, 2014 
*Self-efficacy for Appropriate Medication Adherence Scale (SEAMS).
Reliability 
The analysis indicated satisfactory internal 
consistency for the total score and domains of the SEAMS 
– alpha cronbach of 0.8 for the domain of Self-efficacy for 
taking medications, under difficult circumstances and of 
0.9 for the domain of Self-efficacy for continuing to take 
medications when the circumstances which permeate 
this action are uncertain, and of 0.92 for the total score. 
Satisfactory Intraclass Correlation Coefficient (ICC) 
scores were calculated for the domains and total score 
of the Brazilian version of the SEAMS (Table 3).
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Construct Validity
Convergent validity 
Significant inverse correlations of moderate to 
strong magnitude were observed between the total 
score and the domains of the Brazilian versions of 
the SEAMS and the MMAS-4. Significant correlations 
were not observed between the scores of the Brazilian 
versions of the SEAMS and the GSE. 
SEAMS* - Domains Cronbach alpha Item/total correlation
Alpha -
If item deleted ICC
† CI95%‡
Self-efficacy for taking medications, under difficult 
circumstances 0.8 0.9 [0.7-0.9]
Item 1 0.5 0.8
Item 2 0.6 0.8
Item 3 0.7 0.8
Item 4 0.6 0.8
Item 6 0.6 0.8
Item 7 0.7 0.8
Item 8 0.6 0.8
Self-efficacy for continuing to take medications when the 
circumstances which permeate this act are uncertain 0.9 1.0 [0.9-1.0]
Item 5 0.5 0.9
Item 9 0.8 0.9
Item 10 0.8 0.9
Item 11 0.8 0.9
Item 12 0.8 0.9
Item 13 0.7 0.9
Total score  0.92
Table 3 - Analysis of the reliability of the Brazilian version of the Self-efficacy for Appropriate Medication Adherence 
Scale (n=147). Campinas, SP, Brazil, 2014
*Self-efficacy for Appropriate Medication Adherence Scale – SEAMS; † Intraclass Correlation Coefficient (ICC); ‡confidence interval of 95%.
Brazilian version of the SEAMS*
Measure of medication 
adherence Measure of general self-efficacy 
Brazilian version of the 
MMAS-4 Brazilian version of the GSE
†
r‡ R
Domain 1 - Self-efficacy to take medications, under difficult circumstances 
-0.54† 0.12
p<0.0001 p=0.128
Domain 2 - Self-efficacy to continue to take medications when the 
circumstances that permeate this action are uncertain 
-0.43† 0.22
p<0.0001 p=0.0063
Total score 
-0.53† 0.22
p<0.0001 p=0.0071
Table 4 - Spearman correlation coefficients between the scores of the Brazilian versions of the Self-efficacy for 
Appropriate Medication Adherence Scale, the Morisky Self-Reported Measure of Medication Adherence Scale and the 
General Perceived Self-efficacy Scale (n=147). Campinas, SP, Brazil, 2014
*Self-efficacy for Appropriate Medication Adherence Scale (SEAMS); †General Perceived Self-efficacy Scale (GSE); ‡r= correlation coefficient. 
Validity of known or contrasted groups 
The findings evidenced that the Brazilian version of 
the SEAMS was able to discriminate between patients 
who adhered, and those who did not, to the medication 
therapy, according to the global evaluation of the 
adherence – which considers, besides how the medication 
is to be taken (dose, form, frequency and how long for), 
the care for taking the medications. The data showed that, 
in both the domains and total score of the SEAMS, the 
score was significantly greater among those who adhered 
to the medications, in comparison with the nonadherent 
group, indicating greater self-efficacy for drug adherence 
in the adherent group, as previously hypothesized. 
In the same way, the Brazilian version of the SEAMS 
discriminated self-efficacy among patients categorized 
as adequate dose and those considered as insufficient 
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dose, according to the proportion of drug adherence, with 
higher scores in the SEAMS being observed among those 
patients categorized as adequate dose in domains 1 and 
2 (p=0.0051 and p=0.0125, respectively) and total score 
(p=0.0012) of the SEAMS, when compared with those 
with insufficient dose (Table 5).
Domains of 
the SEAMS
Global evaluation 
of adherence n Mean Minimum Q1 Median Q3 Maximum p-value
‡
Domain 1* Adherents 87 20.6 (1.4) 9.0 21.0 21.0 21.0 21.0 <0.0001
Non-adherents 60 19.5 (2.2) 13.0 18.5 21.0 21.0 21.0
Domain 2† Adherents 87 17.6 (1.3) 8.0 18.0 18.0 18.0 18.0 0.0026
Non-adherents 60 16.5 (2.5) 7.0 16.0 18.0 18.0 18.0
Total score 
Total
Adherents 87 38.2 (2.6) 17.0 39.0 39.0 39.0 39.0 <.0001
Non-adherents 60 36.0 (4.3) 22.0 34.0 38.0 39.0 39.0
Proportion of 
adherence
Domain 1 Adequate dose 133 20.3 (1.7) 9.0 21.0 21.0 21.0 21.0 0.0051
Insufficient dose 14 18.9 (2.6) 14.0 18.0 20.0 21.0 21.0
Domain 2 Adequate dose 133 17.4 (1.6) 8.0 18.0 18.0 18.0 18.0 0.0125
Insufficient dose 14 15.2 (3.8) 7.0 13.0 17.5 18.0 18.0
Total score Adequate dose 133 37.7 (3.0) 17.0 38.0 39.0 39.0 39.0 0.0012
Insufficient dose 14 34.1 (5.9) 22.0 33.0 36.5 39.0 39.0
Table 5 - Comparison between the scores of the Brazilian version of the Self-efficacy for Appropriate Medication 
Adherence Scale, according to the global evaluation of medication adherence (n=147). Campinas, SP, Brazil, 2014
*Self-efficacy for taking medications, under difficult circumstances; † self-efficacy for continuing to take medications when the circumstances that permeate 
this action are uncertain; ‡ Mann-Whitney comparison test.
Discussion
In this study, the cultural adaptation of the SEAMS 
was undertaken, and the measurement properties of the 
Brazilian version of the SEAMS were investigated. The 
SEAMS is an instrument constructed with the purpose 
of measuring self-efficacy for medication adherence. 
The methodological procedure of cultural adaptation 
was undertaken in CHD patients, with the semantic-
idiomatic, conceptual and cultural equivalencies of the 
Brazilian version of the SEAMS being determined. 
A ceiling effect was observed for the total score 
and for both domains, indicating that the Brazilian 
version of the SEAMS may not be sensitive for detecting 
improvement of self-efficacy. However, the Brazilian 
version of the SEAMS may be potentially sensitive 
and responsive to measuring worsening, as the floor 
effect was not observed. One possible explanation 
for this finding may be related to the instrument’s 
response scale, whose highly similar options may not 
have made it possible for participants to differentiate 
the alternatives. In previous studies(9,23), in which the 
SEAMS was applied, the evaluation of the instrument’s 
ceiling and floor effect is not found. The present study’s 
findings need to be ratified, as they imply the limitation 
of its use in experimental studies in order to evaluate 
the effect of interventions for the strengthening of self-
efficacy, for medications adherence. 
The majority of the domains of the SEAMS 
presented evidence of internal consistency, with the 
Cronbach alpha oscillating between 0.85 and 0.90, a 
finding observed in a previous study involving patients 
with coronary heart disease(9). The item/total correlation 
analyses, as well as the observation that the removal of 
items does not significantly improve the Cronbach alpha 
coefficient, reinforce the homogeneity of the items in 
each domain. The reliability was also tested through 
the test-retest, with evidence being obtained of the 
measure’s temporal stability. However, studies involving 
the application of the SEAMS in other populations, for 
evaluation of the instrument’s measurement properties, 
were not found in the literature. 
In the present study, evidence of the construct 
validity of the SEAMS was supported by the analyses 
of correlation between the SEAMS scores and those 
of the MMAS-4. However, correlations were not found 
between the domains of the SEAMS and the measure 
of general self-efficacy through the GSE. This absence 
of correlation may be explained by the fact that this 
scale measures self-efficacy in a generic way, that is, 
the items of the scale refer to how to deal with success 
in a specified situation, while the SEAMS evaluate self-
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efficacy for a specific behavior – medication adherence. 
However, it is emphasized that negative correlations of 
moderate to strong magnitude were observed between 
the SEAMS and the MMAS-4, which suggests convergent 
construct validity(9).
In relation to the validity of known groups, it was 
observed that the dimensions and total score of the 
SEAMS discriminated between CHD patients classified 
as “adherent” and “non-adherent”. Therefore, the 
sensitivity of the SEAMS, in the detection of differences 
between the groups, suggests that this instrument may 
be responsive, that is, capable of measuring changes in 
self-efficacy for medication adherence, over time. Data 
were not found in the literature relating to the validity of 
known groups of the SEAMS.
Self-efficacy is an important construct which can, 
partly, explain the behavior of medication adherence in 
CHD patients, as well as being particularly relevant as it 
is potentially modifiable(7), being able to be the basis for 
the development of interventions related to behavioral 
change(24).
The measurement provided by the SEAMS has 
potential applications for clinical practice and for research. 
In relation to the clinical implications, this instrument 
could be used for identifying specific situations, related 
to the patient’s beliefs regarding the perception of her 
capacity to take the medications, as prescribed by the 
doctor, which configured challenges for adherence to the 
medication treatment, in this way making it possible to 
guide the health professional’s actions with a view to 
strengthening self-efficacy for medication adherence.
As a result, the effectiveness of interventions which 
strengthen self-efficacy, such as those based in active 
learning, undertaken through vicarious reinforcement, 
when the educator shows the patient that other 
individuals like her are able to adopt the behavior, 
as well as those of verbal persuasion, in which the 
professional reinforces that the individual is capable of 
undertaking such an action, as well as actions directed 
towards eliminating barriers, must be evaluated through 
a reliable tool, such as the Brazilian version of the 
SEAMS. Individuals with high self-efficacy apply greater 
efforts in coping with barriers, in comparison with those 
with a low self-efficacy(25).
As a research tool, the measurement of self-efficacy 
provided by the SEAMS could be a valuable variable of 
outcome, which could be measured over time in response 
to a cognitive or educational behavioral intervention, 
providing evidence regarding the effect of interventions, 
as well as contributing to a better understanding of the 
constructs which determine adherence. In this regard, 
the scale may be used in studies which aim to extend 
knowledge regarding the mediating and/or moderating 
variables of this complex behavior. 
As limitations, the absence in the present study 
of the use of an objective measurement of medication 
adherence, as well as the use of a generic measurement 
of evaluation of self-efficacy, are indicated. A review of 
the literature evidences that none of the measures used 
for evaluating medication adherence are completely 
satisfactory, the combined use of objective and 
subjective measurements of adherence being indicated 
for this reason(26). Although an objective measurement 
of medication adherence was not used, it is emphasized 
that more than one self-reported measure was used, 
with a view to obtaining a more accurate evaluation of 
medication adherence. 
As a result, this study provides a tool with evidence 
of reliability and validity for measuring self-efficacy, 
for medication adherence, which could be useful in the 
evaluation of this construct, after nursing interventions 
directed towards the improvement of self-efficacy for 
medication adherence.
Conclusion
This study provides evidence that the Brazilian 
version of the Self-efficacy for Appropriate Medication 
Adherence Scale (SEAMS) is an instrument which is easy 
to understand, and whose measurement properties are 
reliable and valid. The findings evidence reliability of the 
total score and of its domains. The construct validity was 
supported through negative correlations of moderate 
to strong magnitude between its constructs and the 
measure of medication adherence (the Brazilian version 
of the MMAS-4), although evidence was not found for 
correlations between the Brazilian version of the SEAMS 
and the general measure of self-efficacy. The validity 
of known groups was also supported, as the scale is 
capable of differentiating self-efficacy for adherence 
among those who were adherent and nonadherent to 
the medications. However, a high percentage of ceiling 
effect was observed, suggesting that the Brazilian 
version of the SEAMS may not be sensitive for detecting 
improvement in self-efficacy for medication adherence. 
It is recommended that further studies be undertaken 
with adaptation of the response scale of the Brazilian 
version of the SEAMS, and broadening of the sample, 
with a view to ratifying the findings related to the ceiling 
effect, as well as to confirm the structure of factors of 
the Brazilian version of the SEAMS.
www.eerp.usp.br/rlae
10 Rev. Latino-Am. Enfermagem. 2016;24:e2692
References
1. American Heart Association. Heart disease and stroke 
statistics - 2013 update: a report from the American 
Heart Association. Circulation 2013;127(1):e6-e245. 
2. Zeymer U, Junger C, Zahn R, Bauer T, Bestehorn 
K, Senges J, et al. Effects of a secondary prevention 
combination therapy with an aspirin, an ACE inhibitor 
and a statin on 1-year mortality of patients with acute 
myocardial infarction treated with a beta-blocker. 
Support for a polypill approach. Curr Med Res Opin. 
2011;27(8):1563–70. 
3. Steg PG, James SK, Atar D, Badano LP, Blomstrom- 
Lundqvist C, Borger MA, et al. ESC Guidelines for the 
management of acute myocardial infarction in patients 
presenting with ST-segment elevation. Eur Heart J. 
2012;33(20):2569–19. 
4. Haynes RB, Yao X, Degani A, Kripalani S, Garg 
A, McDonald HP. Interventions for enhancing 
medication adherence. Cochrane Database Syst Rev. 
2005;19(4):CD000011.
5. World Health Organization. Adherence to Long-term 
Therapies: Evidence for Action. Geneva, Switzerland: 
World Health Organization; 2003.
6. Leventhal H, Cameron L. Behavioral theories and 
the problem of compliance. Patient Educ Couns. 
1987;10:117–38.
7. Bandura A. Social foundations of thought and action: 
A social cognitive theory. New Jersey: Prentice Hall; 
1986.
8. Osterberg L, Blaschke T. Adherence to medication. N 
Engl J Med. 2005;353(5):487–97.
9. Risser J, Jacobson TA, Kripalani S. Development 
and Psychometric Evaluation of the Self-Efficacy for 
Appropriate Medication Use Scale (SEAMS) in Low-
Literacy Patients With Chronic Disease. J Nurs Meas. 
2007;15(3):203-19.
10. Beaton D, Bombardier C, Guillemin F, Ferraz MB. 
Recommendations for the Cross-Cultural Adaptation of 
the DASH and QuickDASH Outcome Measures. Institute 
for Work and Health, 2007. [Acesso 23 fev 2014]. 
Disponível em http://www.dash.iwh.on.ca/translate2.
htm.
11. Mendez RDR, Rodrigues RCM, Cornélio ME, Gallani 
MCBJ, Godin G. Desenvolvimento de instrumento para 
medida dos fatores psicossociais determinantes do 
comportamento de atividade física em coronariopatas. 
Rev Esc Enferm USP. 2010;44:584-6.
12. Morisky DE, Green LW, Levine MA. Concurrent 
and predictive validity of a self-reported measure of 
medication adherence. Med Care. 1986;24:67-74.
13. Ferreira MCS, Gallani MCBJ. Adaptação transcultural 
do instrumento de Morisky de adesão à medicação para 
pacientes com insuficiência cardíaca. Rev Soc Cardiol 
Estado de São Paulo. 2006;16:116.
14. Ventura-Cerdá JM, Mínguez-Gallego C, Fernandez-
Villalba EM, Alós-Almiñana M, Andrés-Soler J. Escala 
simplificada para detectar problemas de adherencia 
(ESPA) al tratamiento antirretroviral. Farm Hosp. 
2006;30(3):171-6.
15. Januzzi FF. Qualidade de vida relacionada à função 
visual e adesão medicamentosa em idosos com 
retinopatia diabética [Dissertação - Mestrado]. Campinas 
(SP): Universidade Estadual de Campinas; 2009.
16. Schwarzer R, Jerusalem M. Generalized Self-Efficacy 
Scale. In: Weinman J, Wright, Johnston M, editors. 
Measures in health psychology: A user’s portfolio - 
Causal and control beliefs. Windsor: Nfer-Nelson; 1995. 
p. 35-7.
17. Souza I, Souza MA. Validação da Escala de 
Autoeficácia Geral Percebida. Rev Univ Rural: Série 
Ciências Humanas. 2004;26(1-2):12-7.
18. Scientific Advisory Committee of the Medical 
Outcomes Trust. Assessing health status and quality-of-
life instruments: attributes and review criteria. Qual Life 
Res. 2002;1(3):193–205.
19. Bennett SJ, Oldridge NB, Eckert GJ, Embree JL, 
Browning S, Hou N, et al. Discriminant properties of 
commonly used quality of life measures in heart failure. 
Qual Life Res. 2002;11(4):349-59.
20. Nunnally JC. Psychometric theory. New York: 
McGraw-Hill; 1978. 640 p.
21. Fayers PM, Machin D. Quality of life: assessment, 
analysis and interpretation. England: John Wiley; 2000. 
404 p.
22. Ajzen I, Fishbein M. How to define and measure 
behavior. In: Ajzen I, Fishbein M. Understanding 
attitudes and predicting social behavior. Upper Saddle 
River: Prentice-Hall; 1980. p. 28-39.
23. Kripalani S, Schmotzer B, Jacobson TA. Improving 
Medication Adherence through Graphically Enhanced 
Interventions in Coronary Heart Disease (IMAGE-
CHD): a randomized controlled trial. J Gen Intern Med. 
2012;27(12):1609-17. 
24. Baranowski T. Reciprocal determinism at the stages 
of behavior change: an integration of community, 
personal and behavioral perspectives. Int Q Commun 
Health Educ. 1989;10(4):297–327.
25. Bartholomew LK, Parcel GS, Kok G, Gottlieb NH. 
Planning Health Promotion Programs: An Intervention 
Mapping Approach. 2th ed. Califórnia: Jossey-Bass; 
2006.
www.eerp.usp.br/rlae
11Pedrosa RBS, Rodrigues RCM.
Received: May 22nd 2014
Accepted: July 25th 2015
Copyright © 2016 Revista Latino-Americana de Enfermagem
This is an Open Access article distributed under the terms of the 
Creative Commons (CC BY).
This license lets others distribute, remix, tweak, and build upon 
your work, even commercially, as long as they credit you for the 
original creation. This is the most accommodating of licenses 
offered. Recommended for maximum dissemination and use of 
licensed materials.
Corresponding Author:
Rafaela Batista dos Santos Pedrosa
Universidade Estadual de Campinas. Faculdade de Enfermagem
Rua Tessália Vieira de Camargo, 126
Cidade Universitária
CEP: 13083-887, Campinas, SP, Brasil
E-mail: rafasantosenf@gmail.com
26. Ye S, Krupka DJ, Davidson KW. Diagnosing 
medication non-adherence in patient with myocardial 
infarction. Front Psychol. 2012;3(3):267.
